

表 4.6 Effects of gypenosides on N-acetyltransferase activity in vitro

Gypenosides Treatment	AAF (nmol/min/mg protein)					
	Blood	Liver	Lung	Bladder	Colon	Uterus
Control	0.34 ± 0.08	1.59 ± 0.30	0.80 ± 0.26	0.50 ± 0.14	0.64 ± 0.12	0.59 ± 0.12
200	0.24 ± 0.08	1.44 ± 0.28	0.72 ± 0.22	0.46 ± 0.11	0.60 ± 0.10	0.50 ± 0.10
300	0.20 ± 0.06	1.30 ± 0.22	0.60 ± 0.14	0.30 ± 0.09	0.38 ± 0.09	0.40 ± 0.08
350	0.14 ± 0.06	0.94 ± 0.16	0.46 ± 0.10	0.21 ± 0.06	0.24 ± 0.06	0.27 ± 0.06
400	0.09 ± 0.04 ^a	0.75 ± 0.10	0.31 ± 0.08 ^{ab}	0.14 ± 0.04 ^{ab}	0.18 ± 0.04 ^{ab}	0.16 ± 0.04 ^{ab}
450	0.04 ± 0.02 ^{ab}	0.42 ± 0.08 ^a	0.18 ± 0.04 ^{ab}	0.09 ± 0.02 ^{ab}	0.10 ± 0.02 ^{ab}	0.12 ± 0.02 ^{ab}
F value	7.40	14.97	8.21	16.42	8.16	7.84

Values are mean ± SD of activity (nmol/min/mg protein); n = 6. ANOVA analysis used for comparison.

^a Significantly different, at *p* level of 0.05, when compared to control.

^b Significantly different, at *p* level of 0.05, when compared to 200 µg/ml gypenosides.